ANPCF News and Press, Angle

CelLBxHealth strengthens cost discipline by aligning FDA regulatory approach with current commercial needs GUILDFORD, SURREY / ACCESS Newswire / February 13, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumor cell (CTC) intelligence, with tests and services supporting resea...

GUILDFORD, SURREY / ACCESS Newswire / January 16, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces an update on 2025 unaudited financial results and further...

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 Decem...

GUILDFORD, SURREY / ACCESS Newswire / December 23, 2025 / Cellbxhealth PLC: TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0034330679 Issuer Name CelLBxHealth plc UK or Non-UK Issuer UK 2. Reason for Notification An acquis...

2025-12-01 18:53:25 ET CelLBxHealth plc (ANPCY) Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 AM EST... Read the full article on Seeking Alpha For further details see: CelLBxHealth plc (ANPCY) Discus...

CelLBxHealth presents proof-of-concept study using Roche Tissue Diagnostics' workflow at world-leading drug development conference Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast)...

Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years CTCs provide distinct and impactful information...

GUILFORD, SURREY, AL / ACCESS Newswire / October 16, 2025 / ANGLE plc (to be renamed CelLBxHealth plc) (AIM:AGL)(OTCQX:ANPCY), a world-leading circulating tumour cell (CTC) intelligence company with tests for use in research, drug development and clinical oncology, announces that it has streng...

Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman and recognised oncology diagnostic industry veteran, to lead company as Executive Chair...

CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients GBM CTC isolation only possible with Parsortix label-free methodology Data presented at the 7 th ACTC meeting GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-lead...